Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108033 | 0.90 | RAB9A (0.55) | SRD5A2POLBGAAELANEMEN1 | |
| SCHEMBL12544643 | 0.87 | RAB9A (0.56) | SRD5A2POLBMEN1LMNAMAPT | |
| SCHEMBL12239728 | 0.87 | RAB9A (0.50) | SRD5A2POLBGAAMEN1LMNA | |
| SCHEMBL13355627 | 0.84 | MEN1 (0.68) | SRD5A2POLBMEN1LMNAMAPT | |
| SCHEMBL13021244 | 0.83 | SRD5A2 (0.63) | SRD5A2GAALMNAMAPTRAB9A | |
| SCHEMBL12239725 | 0.83 | LTA4H (0.50) | SRD5A2MEN1RAB9AKMT2APARP10 | |
| SCHEMBL12216703 | 0.83 | LTA4H (0.44) | RAB9APARP10PGR | |
| SCHEMBL12240445 | 0.83 | LTA4H (0.44) | RAB9APARP10PGR | |
| SCHEMBL13943794 | 0.83 | LTA4H (0.50) | SRD5A2MEN1RAB9AKMT2APARP10 | |
| SCHEMBL12240007 | 0.83 | LTA4H (0.50) | SRD5A2MEN1RAB9AKMT2APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039630-B2 | Cationic compound, dye compound and method of using the same, and optical information recording medium | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080274423-A1 | OPTICAL INFORMATION RECORDING MEDIUM AND METHOD OF RECORDING INFORMATION | FUJIFILM CORPORATION (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | RRS1, RPS3, ADRM1 | SRD5A2 226/4885POLB 3792/4885ACACB 4004/4885 |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | CHRM1, CHRM2, TRPC6 | SRD5A2 1298/4885POLB 4597/4885ACACB 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.